<DOC>
	<DOCNO>NCT02222610</DOCNO>
	<brief_summary>The purpose study assess tolerability efficacy ranibizumab treatment administer subject radiation retinopathy</brief_summary>
	<brief_title>Study Efficacy Tolerability Intravitreal Injections Ranibizumab Compared Intravitreal Injections Ranibizumab Combined With Targeted Retinal Photocoagulation Treat Radiation Retinopathy .</brief_title>
	<detailed_description>RRR phase II , randomize , multicenter , clinical study assess tolerability efficacy ranibizumab treatment administer subject radiation retinopathy . Subjects randomize one 3 arm ; IVT monthly vs. ranibizumab treatment administer IVT monthly combine peripheral target photocoagulation vs. ranibizumab treatment administer IVT three month follow need treatment ranibizumab combine peripheral target photocoagulation 48 week . From week 52 week 101 , 3 treatment arm employ treat extend protocol IVT ranibizumab treatment .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion Criteria Subjects eligible participate follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Active radiation retinopathy result form radiation treatment perform within last 3 year . Radiation retinopathy define follow : retinal hemorrhage , exudate , edema , and/or neovascularization , attributable cause . Best Corrected Visual Acuity ( BCVA ) 20/2520/400 study eye Exclusion Criteria Subjects meet follow criterion exclude study : Pregnancy ( verify positive pregnancy test ) lactation Premenopausal woman use adequate method contraception . The following consider effective mean contraception : surgical sterilization , use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , intrauterine device ( IUD ) , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Participation simultaneous medical investigation trial Previous participation study involve investigational drug within 30 day Day 0 ( exclude vitamin mineral ) . History allergy fluorescein , amenable treatment Previous intravitreal treatment antivascular endothelial growth factor ( VEGF ) drug within 60 day Day 0 Previous intravitreal subconjunctival treatment cortical steroid within 90 day Day 0 History vitrectomy History treatment one form radiation eye ( e.g . proton beam therapy plaque therapy ) . Subjects 7 disc diameter ischemia central macula would hinder visual acuity improvement History panretinal photocoagulation treatment study eye . Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze Any concurrent intraocular condition study eye , opinion investigator , could : Require medical surgical intervention 12 month study period prevent treat visual loss might result condition . Contribute loss least 2 Snellen equivalent line BCVA 12month study period , allow progress untreated . Active intraocular inflammation ( grade 2+ ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( stage 3 4 ) study eye . Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye . Aphakia absence posterior capsule study eye . Intraocular surgery ( include cataract surgery ) study eye within 2 month precede Day 0 . Uncontrolled glaucoma study eye ( defined intraocular pressure ( IOP ) &gt; 30 mmHg despite treatment antiglaucoma medication ) . History glaucomafiltering surgery study eye History corneal transplant study eye Uncontrolled blood pressure ( define systolic and/or diastolic &gt; 180/110 mmHg subject seat ) . If subject 's initial reading exceeds value , second reading may take least 30 minute later . If subject require antihypertensive medication , subject become eligible medication take continuously least 14 day prior Day 0 blood pressure le 180/110 mmHg . New diagnosis atrial fibrillation manage subject 's primary care physician cardiologist within 3 month Day 0 . History stroke within last 3 month Day 0 . History myocardial infarction within 3 month Day 0 . History disease , metabolic dysfunction , physical examination find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . Current treatment active systemic infection Active malignancy uveal melanoma Presence metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Radiation Retinopathy</keyword>
</DOC>